<DOC>
	<DOCNO>NCT03093701</DOCNO>
	<brief_summary>Subjects macular edema screen eligible subject enrol receive single dose study drug ( TLC399 ) either three dose strength intravitreal ( IVT ) route . Each three group include approximately 22 subject . The subject follow visual acuity , safety , tolerability retinal thickness assessment single IVT injection study drug Day 1 .</brief_summary>
	<brief_title>TLC399 ( ProDex ) Subjects With Macular Edema Due Retinal Vein Occlusion ( RVO )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Be male female , least 18 year age . Have macular edema due CRVO BRVO Have bestcorrected visual acuity ( BCVA ) score 20/40 20/400 Have mean central subfield thickness ( CST ) â‰¥350 um Be willing able comply study procedure sign write informed consent . Must agree use medically acceptable form birth control Poorly control diabetes History significant intraocular pressure ( IOP ) elevation steroid treatment History ocular hypertension glaucoma Cataract surgery study eye within 3 month , intraocular surgery within 6 month prior Screening Visit Use hemodilution treatment RVO Use IVT ranibizumab bevacizumab study eye within 6 week prior Screening Visit ; IVT aflibercept within 8 week prior Screening Visit . IVT Ozurdex study eye within 6 month prior Screening Visit . Prior use Retisert Iluvien Use systemic steroid heparin within 1 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>